Pharmaceutical Lobby Chief Steve Ubl Announces Departure

Ubl's exit from PhRMA signals potential shifts in drug industry's Washington influence

Apr. 10, 2026 at 7:13pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of pill bottles, a syringe, and a stethoscope arranged on a clean, white background, symbolizing the abstract corporate strategy and regulatory challenges facing the pharmaceutical industry.As the pharmaceutical industry faces heightened scrutiny, the departure of a longtime lobbyist signals a potential shift in how Big Pharma navigates the complex political landscape.Washington Today

Steve Ubl, the longtime head of the powerful pharmaceutical industry lobby group PhRMA, has announced his plans to depart the organization by the end of 2026. Ubl's departure after nearly a decade at the helm comes amid growing scrutiny and shifting dynamics for the drug industry in Washington, raising questions about the future direction of PhRMA's advocacy efforts.

Why it matters

Ubl's exit marks a significant moment, as he has been a central figure in shaping policy around drug pricing, innovation, and access during a consequential period for the pharmaceutical industry. His departure hints at potential recalibration of how the industry navigates the complex political landscape in the nation's capital, where direct executive engagement and national security concerns have become part of the drug pricing equation.

The details

Ubl has led PhRMA, the Pharmaceutical Research and Manufacturers of America, since September 2015 after over a decade leading the medical device trade lobby. His tenure has seen immense upheaval and intense scrutiny for the drug industry, with PhRMA's lobbying spending hitting a record $38 million last year. However, there's been a sense of frustration among lobbyists regarding the industry's declining clout, particularly during the Trump administration, which favored direct negotiations with pharmaceutical executives over traditional lobbying channels.

  • Steve Ubl announced plans to depart PhRMA by the end of 2026.
  • Ubl has led PhRMA since September 2015 after over a decade leading the medical device trade lobby.

The players

Steve Ubl

The longtime head of the powerful pharmaceutical industry lobby group PhRMA, who has announced plans to depart the organization by the end of 2026.

Rob Davis

The chair of the PhRMA board, who lauded Ubl's leadership and commitment to a 'strong, seamless transition' as he departs the organization.

PhRMA

The Pharmaceutical Research and Manufacturers of America, a powerful lobby group representing the pharmaceutical industry.

Got photos? Submit your photos here. ›

What they’re saying

“Ubl himself expressed pride in accomplishments and a commitment to the industry and patients.”

— Steve Ubl

“Merck CEO Rob Davis, as chair of the PhRMA board, lauded Ubl's leadership and commitment to a 'strong, seamless transition' as he departs the organization.”

— Rob Davis, Merck CEO, PhRMA Board Chair

What’s next

The PhRMA board will work to ensure a smooth transition as they search for Ubl's successor, with the goal of maintaining stability and continuity in the organization's leadership during a period of significant political and economic pressures for the pharmaceutical industry.

The takeaway

Steve Ubl's departure from the helm of PhRMA signals a potential recalibration of the pharmaceutical industry's approach to navigating the complex political landscape in Washington, where traditional lobbying models may be less effective in the face of evolving dynamics like direct executive engagement and national security concerns around drug pricing.